True	Crab 4run o	Ann Arbor	tumor		ctDNA			Tissue	
Туре	Subtype	stage	fraction	Gene	HGVSc	VAF	Gene	HGVSc	VAF
Tissue	FL #1	3	95%	KMT2D	c.435G>A	2.6%	KMT2D	c.435G>A	8.0%
matched				TNFAIP3	c.175_176del	1.2%	TNFAIP3	c.175_176del	0.9%
				SOCS1	c.348C>A	2.5%	SOCS1	c.348C>A	7.5%
							SOCS1	c.125G>A	7.6%
							KMT2C	c.4508-6T>G	7.6%
							BTG1	c.149-9C>A	5.4%
							B2M	c.2T>C	3.8%
							B2M	c.22del	3.4%
							NFKB2	c.694C>T	0.9%
	FL #2	3	95%	IRF8	c.64A>T	0.6%			
							CREBBP	c.4391T>A	37.2%
							CREBBP	c.4369T>G	36.2%
							BCL2	c.157_158delinsTT	33.3%
							FOXO1	c.71C>T	32.5%
						CREBBP c.4447dup	c.4447dup	25.3%	
							PIM1	c.225del	24.0%
							BCL2	c.163C>A	12.4%
							FOXO1	c.64T>C	4.7%
							CREBBP	c.4390_4391delinsCA	3.0%
							TCF3	c.1094-6T>G	2.8%
							CIITA	c.902C>T	0.4%
	DLBCL #1	4	60%	TNFRSF14	c.3G>A	82.6%	TNFRSF14	c.3G>A	68.0%
				ID3	c.211C>T	11.0%		c.211C>T	29.0%
				NFKBIA	c.802C>T	45.0%	NFKBIA	c.802C>T	38.7%
				TP53	c.857A>G	67.0%	TP53	c.857A>G	64.2%
				ID3	c.166C>T	4.1%		c.166C>T	29.1%
				JAK3	c.1216C>T	0.1%	JAK3	c.1216C>T	0.4%
			I	FAS	c.848A>G	41.6%	FAS	c.848A>G	36.6%
				ID3	c.347G>A	16.7%		c.347G>A	5.3%
				ID3	c.300+3A>C	19.4%	ID3	c.300+3A>C	7.0%

S2 Table. NGS results of plasma ctDNA and tumor gDNA from 42 lymphoma patients

EP300	c.5908C>T	49.7%	EP300	c.5908C>T	50.9%
МҮС	c.58G>C	34.0%	MYC	c.58G>C	52.5%
МҮС	c.458T>G	31.0%	МҮС	c.458T>G	51.6%
МҮС	c.488A>C	34.0%	МҮС	c.488A>C	51.9%
NOTCH1	c.1483G>A	50.0%	NOTCH1	c.1483G>A	51.0%
SPEN	c.7750G>T	3.0%			
CD79A	c.567+9A>C	1.9%			
CDKN2A	c.329G>A	1.6%			
HIST1H1E	c.236G>A	1.4%			
ARID1A	c.1985G>A	0.6%			
LRP1B	c.3199G>A	0.5%			
IKZF3	c.1435C>T	0.5%			
IRF8	c.1271T>A	0.3%			
LRP1B	c.1421C>T	0.2%			
			МҮС	c.653G>A	4.8%
			REL	c.641-1G>T	1.7%
			ARID1A	c.2377A>C	1.4%
			LRP1B	c.6035G>A	1.1%
			BTK	c.868C>T	1.0%
			REL	c.853+1G>A	1.0%
			MTOR	c.5809C>T	0.9%
			KIT	c.2630C>T	0.8%
			BRAF	c.1586C>T	0.8%
			KMT2A	c.10246C>T	0.7%
			SPEN	c.10301C>T	0.7%
			ATM	c.6892G>A	0.7%
			BRAF	c.1768G>A	0.7%
			UBR5	c.3077G>A	0.6%
			NCOR1	c.5635C>T	0.6%
			KIT	c.2902C>T	0.6%
			STAT3	c.1228C>T	0.6%
			UBR5	c.2295G>A	0.5%
			STAT3	c.2237C>T	0.5%
			EZH2	c.2196-1G>A	0.5%

							KMT2D	c.10411C>T	0.5%
							NF1	c.6106G>A	0.5%
							CREBBP	c.2446C>T	0.3%
							MTOR	c.5902C>T	0.3%
	FL #3	3	95%	None			KLHL6	c.268C>T	23.4%
							CREBBP	c.4463C>A	22.4%
							NCOR1	c.3592G>A	0.9%
							MTOR	c.7240G>A	0.6%
							BIRC3	c.934C>T	0.7%
							KMT2D	c.5398G>A	0.3%
							KMT2D	c.3920G>A	0.8%
							STAT6	c.1072G>A	0.5%
							KLHL14	c.259C>A	25.6%
							JAK3	c.1787-7C>T	0.7%
							JAK3	c.1555G>A	0.7%
							ALK	c.1462G>A	0.5%
							KLHL6	c.170T>A	22.9%
							KLHL6	c.247T>G	27.2%
	DLBCL #2	2	95%		SPEN	c.3984_3987del	0.6%		
				NOTCH2	c.7_8delinsTT	4.4%	NOTCH2	c.7_8delinsTT	0.2%
				BTG2	c.136C>G	1.4%	BTG2	c.136C>G	15.8%
				BCL11B	c.1591G>A	3.3%	BCL11B	c.1591G>A	18.3%
				LRP1B	c.1045G>A	1.3%	LRP1B	c.1045G>A	19.2%
							NRAS	c.182A>G	23.5%
							MYC	c.214C>T	20.6%
							GNA13	c.1094C>T	1.6%
							RB1	c.2297C>T	0.4%
	DLBCL #3	2	20%	KMT2D	c.12310C>T	3.6%	KMT2D	c.12310C>T	85.2%
				MYD88	c.794T>C	5.2%	MYD88	c.794T>C	49.9%
				CD79B	c.589T>C	8.3%	CD79B	c.589T>C	91.1%
				ETV6	c.302A>T	2.7%	ETV6	c.302A>T	39.9%
				SF3B1	c.2584G>A	1.3%	SF3B1	c.2584G>A	43.8%
				HIST1H1E	c.394G>A	1.9%	HIST1H1E	c.394G>A	48.1%
			PIM1	c.290G>A	2.4%	PIM1	c.290G>A	44.4%	

				SF3B1	c.2098A>G	0.5%			
				MGA	c.6775A>T	0.5%			
				KIT	c.1771T>G	2.7%			
				PAX5	c.310C>T	3.2%			
							BTG1	c.3G>A	22.0%
	FL #4	4	95%	IRF8	c.1247C>A	1.5%	IRF8	c.1247C>A	22.5%
				KIT	c.1588G>A	1.5%	KIT	c.1588G>A	22.7%
				CREBBP	c.4444T>C	2.0%	CREBBP	c.4444T>C	27.4%
				FOXO1	c.630+9A>G	3.7%	FOXO1	c.630+9A>G	23.1%
				BCL2	c.178G>A	2.2%	BCL2	BCL2 c.178G>A   NCOR1 c.3501+1G>A   NF1 c.7870-1G>A   MTOR c.6527G>A   CREBBP c.2954C>T	
				KMT2D	c.2264G>A	5.4%			
							NCOR1	c.3501+1G>A	1.4%
							NF1	c.7870-1G>A	1.4%
							MTOR	c.6527G>A	1.5%
							CREBBP	c.2954C>T	1.7%
							NF1	c.8417G>T	1.7%
							NF1	c.8425A>T	3.0%
							KMT2C	c.12446C>T	1.0%
							SPEN	c.8455T>A	2.3%
							KMT2D	c.8367-9T>G	28.5%
							IKZF3	c.1019G>A	1.1%
							BCL2	c.386G>A	10.0%
							PLCG1	c.2668A>G	2.3%
							EP300	c.6323A>T	3.1%
							EBF1	c.134+8C>T	22.8%
	FL #5	3	95%	TET2	c.3594_3594+7del	23.5%	TET2	c.3594_3594+7del	0.8%
				IRF8	c.187T>G	1.1%	IRF8	c.187T>G	23.4%
				BTK	c.545G>A	1.8%	BTK	c.545G>A	26.3%
				IKZF3	c.643A>C	3.0%	IKZF3	c.643A>C	20.3%
				CD70	c.143T>A	2.6%	<i>CD70</i>	c.143T>A	38.8%
				CD70	c.140A>G	2.3%	CD70	c.140A>G	39.0%
				CD70	c.97T>C	2.2%	<i>CD70</i>	c.97T>C	41.1%
				EBF1	c.481T>A	1.9%	EBF1	c.481T>A	22.3%
				EBF1	c.193T>A	2.7%	EBF1	c.193T>A	22.2%

				ARID5B	c.1882G>A	2.2%	ARID5B	c.1882G>A	19.8%
				BCOR	c.4780G>A	1.9%	BCOR	c.4780G>A	18.9%
				STAT3	c.1709A>C	0.7%			
							KMT2D	c.16504A>T	13.6%
	DLBCL #4	2	95%	None			BTG2	c.105del	11.8%
	DLDCL #4	2	7570				PIM1	c.114C>G	31.4%
							BCOR c.4780G>A   KMT2D c.16504A>T   BTG2 c.105del   PIM1 c.114C>G   KLHL6 c.125T>G   CREBBP c.4336C>T   CD79B c.589T>G   MYD88 c.794T>C   BTK c.1267G>A   BTG2 c.133G>A   MYD88 c.476G>C   PIM1 c.28G>C   PIM1 c.125C>T   PIM1 c.125C>T   PIM1 c.240+8C>T   PIM1 c.436A>T   PIM1 c.436A>T   PIM1 c.436A>T   PIM1 c.436A>T   PIM1 c.40+8C>T   PIM1 c.436A>T   PIM1 c.607+5G>A   <	50.0%	
							CREBBP	c.4336C>T	30.1%
							CD79B	c.589T>G	37.0%
							MYD88	c.794T>C	29.9%
							BTK	c.1267G>A	18.9%
							BTG2	c.133G>A	58.7%
							MYD88	c.476G>C	31.4%
							PIM1	c.28G>C	33.2%
							PIM1	c.72G>C	39.7%
							PIM1	c.125C>T	31.3%
							PIM1	c.240+8C>T	33.7%
							PIM1	c.241C>T	36.0%
							PIM1	c.436A>T	36.5%
							PIM1	c.607+5G>A	28.9%
							HIST1H1E	c.191A>G	31.4%
							HIST1H1E	c.490G>A	33.0%
							<i>CD70</i>	c.163-10T>C	50.9%
							KLHL6	c.293+6_293+13del	1.7%
	FL #6	3	95%	KMT2D	c.3754C>T	26.1%	KMT2D	c.3754C>T	13.6%
				ARID1A	c.355_365del	16.4%	ARID1A	c.355_365del	0.9%
				KMT2D	c.783del	45.7%	KMT2D	c.783del	14.9%
				CREBBP	c.4507T>A	26.0%	CREBBP	c.4507T>A	9.3%
				EZH2	c.2075C>T	24.9%	EZH2	c.2075C>T	14.9%
				IKZF3	c.793A>G	27.1%	IKZF3	c.793A>G	14.8%
				IKZF3	c.785A>G	27.8%	IKZF3	c.785A>G	15.3%
				BCL2	c.585+8C>T	30.2%	BCL2	c.585+8C>T	12.9%
				BCL2	c.140G>A	36.4%	BCL2	c.140G>A	16.3%
				EBF1	c.20G>C	43.2%			

			SOCS1	c.8C>T	39.6%			
			NFKBIA	c.636+1G>A	2.7%			
			PIM1	c.83-4C>T	1.9%			
						FOXO1	c.553C>T	15.3%
						TNFRSF14	c.36G>A	2.3%
FL #7	2	95%	KMT2D	c.10369_10370del	0.5%	KMT2D	c.10369_10370del	1.8%
			GNA13	c.784A>C	0.6%		c.784A>C	20.7%
						TNFRSF14	c.218C>A	38.7%
						MEF2B	c.248A>T	22.0%
						CD79A	c.534del	20.1%
						GNA13	c.52T>C	18.6%
						GNA13	c.614G>A	17.2%
HL #1	HL #1 4	95%	TP53	c.395A>G	6.0%	TP53	c.395A>G	4.0%
						NOTCH2	c.7_8delinsTT	0.2%
							c.2054G>A	0.6%
						KMT2C	c.2459C>T	3.9%
DLBCL #5	4	20%	RHOA	c.50G>T	9.5%	None		
			TET2	c.2749C>T	9.3%			
			IDH2	c.516G>T	7.2%			
			TET2	c.1774dup	6.5%			
DLBCL #6	1	80%	SPEN	c.4020G>A	8.7%	SPEN	c.4020G>A	18.0%
			B2M	c.346+1G>T	8.9%	B2M	c.346+1G>T	24.2%
			IRF8	c.238A>T	5.3%	IRF8	c.238A>T	17.9%
			RHOA	c.346G>A	11.2%	RHOA	c.346G>A	14.0%
			ITPKB	c.487G>A	6.2%	ITPKB	c.487G>A	12.3%
			SOCS1	c.197G>A	5.3%	SOCS1	c.197G>A	14.6%
			KLHL6	c.1702G>A	16.3%	KLHL6	c.1702G>A	38.4%
			HIST1H1E	c.253A>G	13.4%	HIST1H1E	c.253A>G	31.4%
			CARD11	c.685-7A>G	12.1%	CARD11	c.685-7A>G	20.2%
HL #2	2	90%	BTG1	c.86A>C	9.3%	None		
			TNFAIP3	c.1304dup	7.7%			
			STAT6	c.1260C>A	5.7%			
FL #8	3	95%	BCL2	c.175C>T	5.1%	BCL2	c.175C>T	35.3%
			BCL2	c.140G>A	5.2%			

	FL #9	4	95%	KMT2D	c.10753C>T	29.1%	KMT2D	c.10753C>T	33.4%
				CREBBP	c.4407del	6.1%	CREBBP	c.4407del	22.9%
				EZH2	c.1936T>A	28.5%	EZH2	c.1936T>A	35.1%
				KMT2D	c.15149T>C	35.9%	KMT2D	c.15149T>C	36.0%
				CREBBP	c.4304A>C	29.0%	CREBBP	c.4304A>C	32.6%
				BCL2	c.25T>A	29.3%	BCL2	c.25T>A	40.4%
				NOTCH2	c.710G>A	32.7%	NOTCH2	c.710G>A	35.6%
							KMT2C	c.1181G>A	6.1%
	ENKTL	1	95%	None			DDX3X	c.1628C>G	51.6%
							KMT2D	c.3532C>T	27.0%
							EP300	c.781C>G	14.2%
ctDNA only	DLBCL #7	1	_	RB1	c.1049+8A>G	57.5%			
				NOTCH2	c.6065G>T	19.7%			
				PIM1	c.83-5C>T	17.3%			
				PIM1	c.82+8C>T	17.1%			
				PIM1	c.544C>G	16.0%			
				DTX1	c.90G>C	15.8%			
				LRP1B	c.5954C>T	14.6%			
				KMT2C	c.995A>G	6.7%			
	FL #10	1	-	None					
	MZL	1	-	KMT2C	c.2741G>A	5.5%			
				DIS3	c.2259C>A	0.2%			
	FL #11	1	-	None					
	DLBCL #8	4	-	ASXL3	c.5204G>C	11.1%			
				ASXL3	c.5202del	6.7%			
				TET2	c.290_291del	6.0%			
				B2M	c.199G>T	5.7%			
				B2M	c.358T>A	2.5%			
				STAT3	c.2144C>T	0.9%			
				CD58	c11_25del	0.4%			
				ASXL1	c.2197C>T	0.4%			
	DLBCL #9	1	-	TNFRSF14	c.62T>A	28.2%			
		1		DDX3X	c.1679T>G	16.1%			
				STAT3	c.1696G>A	13.7%			

			B2M	c.38T>G	13.1%
			KLHL6	c.1639G>A	11.3%
			HIST1H1E	c.193G>A	8.4%
			SGK1	c.202C>G	7.6%
			B2M	c.68-2A>G	7.5%
			TET2	c.3850dup	7.4%
			TET2	c.2207C>G	7.1%
			SGK1	c.228+6T>G	5.8%
			SOCS1	c.70G>C	2.5%
			SOCS1	c.46G>A	2.4%
			EGR1	c.71C>G	2.3%
			SOCS1	c.49G>C	2.0%
			BTG2	c.142+5_142+7delinsACA	1.5%
			KLHL6	c.244G>A	1.4%
			IRF8	c.259A>T	1.0%
			IRF8	c.163T>G	0.7%
			SGK1	c.333+3A>T	0.4%
			PTEN	c.29G>T	0.3%
			REL	c.908T>G	0.3%
			DNMT3A	c.2228C>T	0.1%
DLBCL #10	4	-	DDX3X	c.1574A>G	84.4%
			DTX1	c.82T>A	42.0%
			SOCS1	c.483G>A	38.4%
			TNFRSF14	c.303_304+1delinsTGT	36.9%
			ATM	c.2318T>C	34.5%
			KLHL6	c.1639G>A	33.4%
			BTG2	c.19A>G	32.5%
			TET2	c.3893G>A	32.0%
			BTG2	c.25A>G	31.5%
			MYD88	c.617C>G	31.5%
			FOXO1	c.578G>A	31.4%
			EGR1	c.188G>C	30.7%
			IRF8	c.238A>G	29.5%
			CD58	c.94C>T	28.1%

				DTX1	c.2T>C	28.0%	
				KMT2A	c.12C>G	27.8%	
				FOX01	c.469_470delinsTA	19.5%	
				TET2	c.940 943del	16.0%	
				CD58	c.91dup	14.7%	
	DLBCL #11	3	-	SPEN	c.2992C>T	18.0%	
				NCOR1	c.1915_1915+2delinsAGG	8.1%	
				DNMT3A	c.1475-1G>A	1.0%	
				TP53	c.713G>A	0.2%	
	DLBCL #12	1	_	MYD88	c.794T>C	27.7%	
	DEDCE #12	1	-	TBL1XR1	c.809T>C	24.5%	
				CD79B	c.589T>A	23.3%	
				EGFR	c.754C>T	18.5%	
				TP53	c.743G>A	15.4%	
				PIM1	c.183C>G	7.6%	
				PIM1	c.62_77del	4.8%	
				PIM1	c.241C>T	2.4%	
				SGK1	c.750C>G	1.4%	
				DNMT3A	c.1508_1516delinsAA	1.2%	
				DTX1	c.259+5G>A	1.1%	
				SGK1	c.152+1G>A	1.0%	
				SGK1	c.101G>A	0.9%	
				IRF4	c.178C>T	0.7%	
	Mycosis	3		PTEN	c.16A>T	0.7%	
	fungoides		-	BIRC6	c.6309G>A	0.4%	
				LRP1B	c.8610C>A	0.2%	
				MTOR	c.3837C>G	0.1%	
	HL #3	3	-	TET2	c.5158A>T	26.5%	
				TET2	c.1882G>T	26.4%	
				RHOA	c.50G>T	12.6%	
				IDH2	c.515G>A	11.1%	
				PLCG1	c.1522C>T	10.2%	
				BTK	c.946A>G	6.7%	

				KDM6A	c.4075C>T	4.2%
-	FL #12	3	-	CREBBP	c.4508A>T	21.6%
				KMT2D	c.5707C>T	9.7%
				BCL2	c.140G>A	7.7%
				TNFRSF14	c.500dup	7.6%
				KMT2D	c.15446_15447del	6.4%
				ASXL3	c.6493A>C	1.8%
				CD79B	c.553-1G>A	0.4%
	HL #4	4	-	None		
	DLBCL #13	4		DDX3X	c.707T>C	14.3%
	DLDCL #15	4	-	BIRC6	c.5896G>T	6.7%
				ITPKB	c.574G>A	5.6%
				ITPKB	c2C>G	5.5%
				STAT3	c.1024G>C	5.5%
				NFKBIA	c.762C>G	5.3%
				NFKBIA	c.202C>T	5.3%
				PIM1	c44G>A	5.2%
				KLHL6	c.262G>A	5.0%
				STAT6	c.1257C>A	4.4%
				IRF8	c.1253dup	4.3%
				ITPKB	c.4G>A	3.3%
				SGK1	c3_4del	2.9%
				ITPKB	c1T>C	2.9%
				KLHL6	c.35_40delinsGGGGTTA	2.8%
				PIM1	c.296G>A	1.9%
				MYD88	c.649G>T	1.4%
				ITPKB	c.163_183del	1.4%
				МҮС	c.158G>C	1.0%
				DNMT3A	c.1015-1G>C	1.0%
				KMT2C	c.976C>T	0.9%
				KIT	c.292A>G	0.5%
				KRAS	c.351A>C	0.4%
				ASXL1	c.2564_2567del	0.3%
	DLBCL #14	2	-	TBL1XR1	c.809T>G	3.2%

			RB1	c.1363C>T	2.9%	
DLBCL #15	4	_	MEF2B	c.769+2T>G	14.3%	
			KLHL6	c.142A>T	10.6%	
			KLHL6	c.1040G>A	10.7%	
			HIST1H1E	c.311C>T	9.9%	
AITL	4	_	TET2	c.2746C>T	66.7%	
	·		DNMT3A	c.2322+1G>A	42.6%	
			IDH2	c.515G>A	16.3%	
			RHOA	c.50G>T	13.8%	
			TET2	c.2702dup	9.6%	
			DNMT3A	c.1429+2T>G	9.4%	
			TET2	c.3500+2dup	9.1%	
			LRP1B	c.12514+1G>A	7.3%	
			FYN	c.526C>T	1.1%	
DLBCL #16	3		BTG1	c.122G>A	6.1%	
DLDCL #10	5	-	BTG1	c.148+2_148+9del	5.8%	
			PIM1	c.155C>T	5.8%	
			KLHL6	c.268C>G	5.3%	
			BTG1	c.42G>C	5.3%	
			ETV6	c.183G>A	5.3%	
			SETD2	c.4380del	5.2%	
			MYD88	c.734C>T	4.8%	
			BCL2	c.133G>A	4.2%	
			CD79B	c.589T>C	3.9%	
			PIM1	c.190-8G>A	3.8%	
			PIM1	c.72G>C	3.7%	
			PIM1	c.182A>G	3.6%	
			BTG2	c.191G>C	3.5%	
			BTG2	c.213_214delinsTT	3.3%	
			MYD88	c.390G>C	2.0%	
			DNMT3A	c.2597+1G>A	1.0%	
DLBCL #17	1	-	DNMT3A	c.2222C>A	2.9%	
HL #5	3	-	KMT2A	c.10074T>A	2.9%	
			ASXL3	c.1888G>A	1.8%	

				MGA	c.3480G>A	1.1%	
				TRAF3	c.1206G>A	0.7%	
	DLBCL #18	4		EP300	c.4355C>T	18.8%	
	DLDCL #18	4	-	TNFRSF14	c.388C>T	16.6%	
				KMT2D	c.10804C>T	15.9%	
				TP53	c.716A>G	7.6%	
				ARID1A	c.283 326del	4.0%	
				KMT2D	c.2456dup	2.9%	
				BTG1	c.68C>T	2.4%	
				EP300	c.5195G>A	2.4%	
				TNFAIP3	c.1223C>G	2.1%	
				BCL2	c.386G>A	1.6%	
				KLHL6	c.1460A>G	1.6%	
				BCL2	c.408G>C	1.4%	
			-	EZH2	c.2075C>T	0.7%	
				TNFAIP3	c.1475dup	0.5%	
	DLBCL #19	3	3 _	BTK	c.545G>A	70.0%	
	DEDCE #17	5	-	MYD88	c.794T>C	64.6%	
				TBL1XR1	c.971_973del	40.6%	
				LRP1B	c.6839G>A	24.9%	
				CD58	c.498T>A	22.9%	
				HIST1H1E	c.566C>T	21.5%	
				TP53	c.814_841del	21.2%	
				PIM1	c.4C>G	20.3%	
				CD58	c.352_355del	18.4%	
				PIM1	c.290G>A	16.3%	
				BTG1	c.148+6C>T	11.0%	
				SGK1	c.12G>A	4.5%	
				PIM1	c.550C>T	4.3%	
				CREBBP	c.4306A>T	0.5%	
	DLBCL #20 3	-	SPEN	c.3434C>A	56.1%		
				FBXW7	c.1484A>C	34.9%	
				HIST1H1E	c.433G>C	30.0%	
			<i>TP53</i>	c.570dup	25.1%		

				HIST1H1E	c.494C>T	24.2%	
				HIST1H1E	c.491C>T	24.1%	
				SOCS1	c.523C>T	22.1%	
				NOTCH2	c.6792C>A	16.2%	
				PIM1	c.607+6C>T	4.8%	
	DLBCL #21	4	-	BTG2	c.28C>T	37.2%	
				BCL2	c.386G>A	31.4%	
				BCL2	c.400G>A	31.0%	
				CREBBP	c.3243dup	30.4%	
				BCL2	c.585+7G>A	26.8%	
				KDM6A	c.4176+1G>C	9.8%	
				TP53	c.375G>A	9.5%	
				B2M	c.358T>G	2.4%	

AITL, angioimmunoblastic T-cell lymphoma; ctDNA, circulating tumor DNA; DLBCL, diffuse large B cell lymphoma; ENKTL, extranodal NK/T cell lymphoma; FL, follicular lymphoma; HGVSc, Human Genome Variation Society nomenclature; HL, Hodgkin lymphoma; MZL, marginal zone lymphoma; NGS, next-generation sequencing; VAF, variant allele frequencies.